本帖最后由 老马 于 2012-1-13 21:20 编辑 % |& t. [$ F7 y
) l, g( c0 x) O8 N4 S3 ?爱必妥和阿瓦斯丁的比较1 ]' M1 B) O4 Z; T U: U5 O
/ ^; B- o7 @1 e* Ohttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
- H1 f! a, b( z
7 M5 [) p% H/ V+ r/ I
4 h. a+ i* U3 b( [, T
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ t9 _6 d& y; E! `) _/ Z/ s2 G1 L==================================================
+ U" I5 y# `8 r# d+ B7 Z! ]: l4 oOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
! y' ~* e6 s% }& Y$ ^Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.3 M$ m/ W, e) B. R; f1 T* e
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* M0 }7 C3 ^, C
|